The Patent Finder

Accera, Inc.

Also on record
Records under this name other than patents Accera, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Accera, Inc.

PatentTitleStatus Expires Confidence
US 10,105,338Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,125,881Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,105,809Enzymatic synthesis of acetoacetate esters and derivatives
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,175,345Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,445,535Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
Formerly held
Term ended
Term ended Mar 4, 2024 · From the USPTO record
Term endedTerm ended Mar 4, 2024From the USPTO record
US 8,124,589Use of ketogenic compounds for treatment of age-associated memory impairment
Formerly held
Term ended
Term ended Jul 14, 2021 · From the USPTO record
Term endedTerm ended Jul 14, 2021From the USPTO record
US 6,835,750Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
Formerly held
Term ended
Term ended May 20, 2021 · From the USPTO record
Term endedTerm ended May 20, 2021From the USPTO record
US 8,426,468Use of medium chain triglycerides for the treatment and prevention of alzheimer'S disease and other diseases resulting from reduced neuronal metabolism
Formerly held
Term ended
Ended no later than May 1, 2021 · From the USPTO record
Term endedEnded no later than May 1, 2021From the USPTO record
US 8,748,400Use of ketogenic compounds for treatment of age-associated memory impairment
Formerly held
Term ended
Ended no later than May 1, 2021 · From the USPTO record
Term endedEnded no later than May 1, 2021From the USPTO record
US 9,603,823Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
Formerly held
Term ended
Ended no later than May 1, 2021 · From the USPTO record
Term endedEnded no later than May 1, 2021From the USPTO record
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited